Advertisement
Advertisement
  • Reuters

    Thermo Fisher says its COVID-19 tests accurately detects Omicron variant

    Thermo Fisher Scientific Inc said on Monday its COVID-19 diagnostic tests can accurately detect the new coronavirus variant Omicron that has made several countries to shut their borders. The World Health Organisation (WHO) last week classified the Omicron variant as a SARS-CoV-2 "variant of concern," saying it may spread more quickly than other forms. Thermo Fisher's TaqPath COVID-19 assays can report accurate results even in the case where one of the gene targets is impacted by a mutation, the company said in a statement.

  • GlobeNewswire

    2021 guidance adjusted to reflect three main impacts

    Nanterre (France), November 29, 2021 2021 GUIDANCE ADJUSTED TO REFLECT THREE MAIN IMPACTS: NEW DOWNWARD REVISION OF AUTOMOTIVE PRODUCTION IN EUROPEDIFFICULTIES TO FLEXIBILIZE AND COMPENSATE STOP-AND-GO GENERATED COSTSONE-OFF COSTS RELATED TO ONE PROGRAM LAUNCH ISSUES IN THE US Faurecia adjusts its 2021 guidance as follows: Sales of between €15bn and €15.5bn with confirmed strong organic sales outperformance of > +600bps (vs. “sales of c. €15.5bn and strong organic sales outperformance > +600bps”

  • GlobeNewswire

    Ease2pay announces intended acquisition of Involtum and capital raise to accelerate growth

    November 29, 2021 THIS PRESS RELEASE CONTAINS INSIDE INFORMATION FOR IMMEDIATE RELEASE. Ease2pay entered into an agreement with Involtum shareholders to acquire Involtum Acquisition of 100% of shares of Involtum Holding B.V. for 10,714,792 to be newly issued shares of Ease2pay Combination of Ease2pay and Involtum activities in line with growth strategy and represents next step towards EV charging business Certain existing Ease2pay and Involtum shareholders commitment to subscribe for new shares